Clinical trial
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
NCT00474513 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00474513 |
|---|---|
| Title | An Imaging Study to Investigate the Distribution of GSK239512 in the Brain. |
| Official title | A PET Study Using [11C] GSK189254 to Establish the Dose, Plasma Concentration and Brain Receptor Occupancy Relationship of GSK239512, a Histamine H3 Antagonist, in Healthy Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Mild Cognitive Impairment, Dementia |
| Intervention type | Drug |
| Interventions | GSK239512 |
| Enrollment | 5 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 17, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: